Resultados de la búsqueda 241-250 of 5781 for Phase

  1. Oncología (médica) - Ensayos clínicos

    In the phase II part, to evaluate the preliminary antitumor activity of two different doses/regimens of [177Lu]Lu-NeoB in combination with capecitabine (dose ...

  2. Oncología (médica) - Ensayos clínicos

    In the phase II part, to evaluate the preliminary antitumor activity of two different doses/regimens of [177Lu]Lu-NeoB in combination with capecitabine (dose ...

  3. Oncología (médica) - Ensayos clínicos

    Phase II Study of NGC-Triple Regimen in Potentially Resectable Pancreatic Cancer Patients. Scottsdale/Phoenix, Ariz., Rochester, Minn. This is a phase II ...

  4. Oncología (médica) - Ensayos clínicos

    The purpose of phase 2a is to establish proof-of-concept (POC) for AG-946 in participants with lower-risk myelodysplastic syndromes (LR-MDS) and to evaluate the ...

  5. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    This phase I trial evaluates the safety, effectiveness, and best dose of onvansertib for the treatment of patients with chronic myelomonocytic leukemia that ...

  6. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    This phase I trial evaluates the safety, effectiveness, and best dose of onvansertib for the treatment of patients with chronic myelomonocytic leukemia that ...

  7. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    This is a phase 1b/2 study of the safety and efficacy of MLN0128 in combination with exemestane or fulvestrant therapy in women with estrogen receptor positive/ ...

  8. Oncología (médica) - Ensayos clínicos

    This phase I trial evaluates the safety, effectiveness, and best dose of onvansertib for the treatment of patients with chronic myelomonocytic leukemia that has ...

  9. Oncología (médica) - Ensayos clínicos

    Phase II Study of NGC-Triple Regimen in Potentially Resectable Pancreatic Cancer Patients. Scottsdale/Phoenix, Ariz., Rochester, Minn. This is a phase II ...

  10. Oncología (médica) - Ensayos clínicos

    The trial will be conducted in 2 parts: an initial Dose Escalation Phase (Part A) of CA-4948 in patients with Relapsed or Refractory Non-Hodgkin Lymphoma, (RR ...